Canlyniadau Chwilio - Dorian M. Cheff

  • Dangos 1 - 10 canlyniadau o 10
Mireinio'r Canlyniadau
  1. 1
    The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1

    The ferroptosis inducing compounds RSL3 and ML162 are not direct inhibitors of GPX4 but of TXNRD1 gan Dorian M. Cheff, Chuying Huang, Karoline Scholzen, Radosveta Gencheva, Michael Ronzetti, Qing Cheng, Matthew D. Hall, Elias S.J. Arnér

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  2. 2
    Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4

    Development of an assay pipeline for the discovery of novel small molecule inhibitors of human glutathione peroxidases GPX1 and GPX4 gan Dorian M. Cheff, Qing Cheng, Hui Guo, Jameson Travers, Carleen Klumpp‐Thomas, Min Shen, Elias S.J. Arnér, Matthew D. Hall

    Cyhoeddwyd 2023
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  3. 3
    Selective cellular probes for mammalian thioredoxin reductase TrxR1: Rational design of RX1, a modular 1,2-thiaselenane redox probe

    Selective cellular probes for mammalian thioredoxin reductase TrxR1: Rational design of RX1, a modular 1,2-thiaselenane redox probe gan Lukas Zeisel, Jan G. Felber, Karoline Scholzen, Lena Poczka, Dorian M. Cheff, Martin S. Maier, Qing Cheng, Min Shen, Matthew D. Hall, Elias S.J. Arnér, Julia Thorn‐Seshold, Oliver Thorn‐Seshold

    Cyhoeddwyd 2022
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  4. 4
    Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors

    Discovery and optimization of piperazine-1-thiourea-based human phosphoglycerate dehydrogenase inhibitors gan Jason M. Rohde, Kyle R. Brimacombe, Li Liu, Michael E. Pacold, Adam Yasgar, Dorian M. Cheff, Tobie D. Lee, Ganesha Rai, Bolormaa Baljinnyam, Zhuyin Li, Anton Simeonov, Matthew D. Hall, Min Shen, David M. Sabatini, Matthew B. Boxer

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  5. 5
    Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity

    Discovery of Orally Bioavailable, Quinoline-Based Aldehyde Dehydrogenase 1A1 (ALDH1A1) Inhibitors with Potent Cellular Activity gan Shyh‐Ming Yang, Natalia J. Martinez, Adam Yasgar, Carina Danchik, C. Johansson, Yuhong Wang, Bolormaa Baljinnyam, Amy Q. Wang, Xin Xu, Pranav Shah, Dorian M. Cheff, Xinran S. Wang, Jacob S. Roth, Madhu Lal‐Nag, James E. Dunford, Udo Oppermann, Vasilis Vasiliou, Anton Simeonov, Ajit Jadhav, David J. Maloney

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  6. 6
    High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2

    High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2 gan Nathan P. Coussens, Stephen C. Kales, Mark J. Henderson, Olivia W. Lee, Kurumi Y. Horiuchi, Yuren Wang, Qing Chen, Ekaterina Kuznetsova, Jianghong Wu, Sirisha Chakka, Dorian M. Cheff, Ken Cheng, Paul Shinn, Kyle R. Brimacombe, Min Shen, Anton Simeonov, Madhu Lal‐Nag, Haiching Ma, Ajit Jadhav, Matthew D. Hall

    Cyhoeddwyd 2018
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  7. 7
    Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling

    Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling gan Amanda Balboni Iniguez, Gabriela Alexe, Emily Jue Wang, Giovanni Roti, Sarvagna Patel, Liying Chen, Samuel Kitara, Amy Saur Conway, Amanda L. Robichaud, Björn Stolte, Pratiti Bandopadhayay, Amy Goodale, Sasha Pantel, Yenarae Lee, Dorian M. Cheff, Matthew D. Hall, Rajarshi Guha, Mindy I. Davis, Marie Ménard, Nicole Nasholm, William A. Weiss, Jun Qi, Rameen Beroukhim, Federica Piccioni, Cory M. Johannessen, Kimberly Stegmaier

    Cyhoeddwyd 2018
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  8. 8
    Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays

    Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays gan Daniel J. Urban, Natalia J. Martinez, Mindy I. Davis, Kyle R. Brimacombe, Dorian M. Cheff, Tobie D. Lee, Mark J. Henderson, Steven A. Titus, Rajan Pragani, Jason M. Rohde, Li Liu, Yuhong Fang, Karavadhi Surendra, Pranav Shah, Olivia W. Lee, Amy Wang, Andrew L. McIver, Hongchao Zheng, Xiaodong Wang, Xin Xu, Ajit Jadhav, Anton Simeonov, Min Shen, Matthew B. Boxer, Matthew D. Hall

    Cyhoeddwyd 2017
    Cael y testun llawn Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  9. 9
    Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH)

    Discovery and Optimization of Potent, Cell-Active Pyrazole-Based Inhibitors of Lactate Dehydrogenase (LDH) gan Ganesha Rai, Kyle R. Brimacombe, Bryan T. Mott, Daniel J. Urban, Xin Hu, Shyh‐Ming Yang, Tobie D. Lee, Dorian M. Cheff, Jennifer Kouznetsova, Gloria A. Benavides, Katie Pohida, Eric J. Kuenstner, Diane K. Luci, Christine Lukacs, D.R. Davies, David M. Dranow, Hu Zhu, Gary A. Sulikowski, William Moore, Gordon M. Stott, Andrew Flint, Matthew D. Hall, Victor Darley‐Usmar, Leonard Μ. Neckers, Chi V. Dang, Alex G. Waterson, Anton Simeonov, Ajit Jadhav, David J. Maloney

    Cyhoeddwyd 2017
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:
  10. 10
    Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties

    Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties gan Ganesha Rai, Daniel J. Urban, Bryan T. Mott, Xin Hu, Shyh‐Ming Yang, Gloria A. Benavides, Michelle S. Johnson, Giuseppe L. Squadrito, Kyle R. Brimacombe, Tobie D. Lee, Dorian M. Cheff, Hu Zhu, Mark J. Henderson, Katherine Pohida, Gary A. Sulikowski, David M. Dranow, Md Kabir, Pranav Shah, Elias Carvalho Padilha, Dingyin Tao, Yuhong Fang, Plamen P. Christov, Kwang‐Ho Kim, Somnath Jana, Pavan Muttil, Tamara L. Anderson, Nitesh K. Kunda, Helen J. Hathaway, Donna F. Kusewitt, Nobu Oshima, Murali Cherukuri, D.R. Davies, Jeffrey P. Norenberg, Larry A. Sklar, William Moore, Chi V. Dang, Gordon M. Stott, Leonard Μ. Neckers, Andrew Flint, Victor Darley‐Usmar, Anton Simeonov, Alex G. Waterson, Ajit Jadhav, Matthew D. Hall, David J. Maloney

    Cyhoeddwyd 2020
    Cael y testun llawn
    Artigo
    Ychwanegu at ffefrynnau
    Wedi'i Gadw mewn:

Offerynnau Chwilio: